MAL Cream

DRUG3 trials

Sponsors

Joint Authority for Päijät-Häme Social and Health Care, Biofrontera Bioscience GmbH, Galderma R&D

Conditions

Actinic KeratosisKeratosis, ActinicMultiple Actinic Keratoses

Phase 3

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

CompletedNCT02799069

Biofrontera Bioscience GmbHActinic Keratosis

Start: 2008-04-30End: 2009-08-31Updated: 2017-04-28

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

TerminatedNCT04269395

Galderma R&DKeratosis, Actinic

Start: 2020-04-07End: 2021-09-01Updated: 2023-10-10

Phase 4

Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)

CompletedNCT01893203

Joint Authority for Päijät-Häme Social and Health CareMultiple Actinic Keratoses

Start: 2013-08-31End: 2014-12-31Updated: 2016-07-11